Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Patients With PL

Overview

About this study

The purpose of this study is to evaluate the effectiveness of daily subcutaneous (SC) metreleptin treatment in subjects with familial partial lipodystrophy (FPLD), and to assess the effect of metreleptin on fasting blood glucose (FBG).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Diagnosis of Familial Partial Lipodystrophy (FPLD)

Exclusion Criteria:

- Previous treatment with metreleptin

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 2/27/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

A.J. Vinaya Simha, M.B.B.S., M.D.

Open for enrollment

Contact information:

Vishakantha Murthy Ph.D., CCRP

(507) 255-8112

Murthy.Vishakantha@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20539464

Mayo Clinic Footer